Top Markets
#1 Nesa Nesa +799.79%
#2 Cortex Cortex +69.18%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.83%
#4 QuantixAI QuantixAI +24.59%
#5 EXOD EXOD +22.78%
#6 Instadapp Instadapp +22.31%
#7 Pons Pons +21.22%
#8 Cash Cat Cash Cat +12.96%
#9 PondCoin PondCoin +12.14%
#10 Fartcoin Fartcoin +11.45%
Coin of the day
Nesa Nesa
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
InflaRx N.V. InflaRx N.V.

InflaRx N.V.

IF0
Rankning i aktier #19672
InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing... InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing in the identification and advancement of C5a inhibitors. Their primary operational territories are Germany and the United States. C5a, an inflammatory mediator, plays a critical role in the advancement of various autoimmune and inflammatory conditions. The company's leading therapeutic candidate, vilobelimab, is an innovative, intravenously administered, first-in-class monoclonal antibody designed to target C5a. This compound has successfully completed Phase III clinical trials for treating hidradenitis suppurativa, a severe, chronic, and debilitating systemic inflammatory skin disease. Furthermore, vilobelimab is undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disorder. An exploratory Phase IIa study is also underway for pyoderma gangraenosum, a persistent inflammatory skin condition. Additionally, vilobelimab is in Phase II clinical development for locally advanced or metastatic cutaneous squamous cell carcinoma that is resistant or refractory to PD-1/PD-L1 inhibitors. Beyond their lead candidate, InflaRx is developing INF904, an oral small molecule drug, intended for currently undisclosed chronic inflammatory and autoimmune diseases. Another pipeline asset, IFX002, is in preclinical stages, targeting chronic inflammation and autoimmune diseases. The company has established strategic alliances, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company was initially known as Fireman B.V. before adopting the name InflaRx N.V. in 2017. Its corporate headquarters are located in Jena, Germany.
Aktiekurs
$3.49
Senast synkroniserad: 2022-08-12
Marknadsvärde
$154.10M
Förändring (1 dag)
12.28%
Förändring (1 år)
0.00%
Land
DE
Handel InflaRx N.V. (IF0)

Kategori

Healthcare
Utdelningsavkastning för InflaRx N.V. (IF0)
Utdelningsavkastningen (TTM) för InflaRx N.V. (aktiesymbol: IF0) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för InflaRx N.V. (IF0) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
Företag Utdelningsavkastning Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH